LTI-03, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s currently in clinical testing, was shown to reduce inflammation and scarring in experiments done on lung tissue collected from IPF patients, according to a study. The study showed that LTI-03’s effects on inflammation and scarring were similar to those of the approved IPF treatment Ofev […] The post LTI-03 reduces inflammation, scarring in IPF lung samples: Study appeared first on Pulmonary Fibrosis News.
